Last reviewed · How we verify
NCT06245785
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
trial testing transarterial chemoembolisation in Hepatic Cancer in 2,200 participants. Completed in 1 December 2023.
1 April 2023
Quick facts
| Lead sponsor | Tang-Du Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,200 |
| Start date | 1 January 2023 |
| Primary completion | 1 April 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 2 locations across China |
Drugs / interventions tested
- transarterial chemoembolisation — full drug profile →
Conditions studied
- Hepatic Cancer — all drugs for Hepatic Cancer →
Sponsor
Tang-Du Hospital
Who can join
18 and older, any sex, with Hepatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. Established practice guidelines for patients with HCC and impaired liver function are lacking. The treatment allocation in these populations is heterogeneous and remains controversial. This study compared the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in patients with HCC and impaired liver function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06245785
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of transarterial chemoembolisation
Trials testing the same drug.
- NCT06245798 — Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension · completed
Other recruiting trials for Hepatic Cancer
Currently open trials in the same condition.
- NCT07034950 — Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation · Phase 1, PHASE2 · active not recruiting
- NCT06492408 — Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. · Phase 2 · recruiting
- NCT06342414 — An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer · recruiting
- NCT05957822 — Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery · Phase 4 · recruiting
Other Tang-Du Hospital trials
Trials by the same sponsor.
- NCT07528235 — An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intraven · Phase 1 · not yet recruiting
- NCT07516522 — Intra-arterial Methylprednisolone After Endovascular Thrombectomy · Phase 2 · recruiting
- NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
- NCT07327736 — Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT · NA · not yet recruiting
- NCT07452601 — Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06245785 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tang-Du Hospital
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06245785.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing